CUDC-101

Suppliers

Names

[ CAS No. ]:
1012054-59-9

[ Name ]:
CUDC-101

[Synonym ]:
7-({4-[(3-Ethynylphenyl)amino]-7-methoxy-6-quinazolinyl}oxy)-N-hydroxyheptanamide
Heptanamide, 7-[[4-[(3-ethynylphenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-N-hydroxy-
CUDC 101
UNII-1A7Y9MP123
7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide
CUDC101
CUDC-101
S1194_Selleck

Chemical & Physical Properties

[ Density]:
1.3±0.1 g/cm3

[ Melting Point ]:
174-177ºC

[ Molecular Formula ]:
C₂₄H₂₆N₄O₄

[ Molecular Weight ]:
434.488

[ Exact Mass ]:
434.195404

[ PSA ]:
109.09000

[ LogP ]:
2.84

[ Appearance of Characters ]:
white

[ Index of Refraction ]:
1.638

[ Storage condition ]:
?20°C

[ Water Solubility ]:
DMSO: soluble

MSDS

Click to get detail MSDS

Safety Information

[ RIDADR ]:
NONH for all modes of transport

Synthetic Route

Click to get detail synthetic route

Articles

Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.

J. Med. Chem. 53 , 2000-2009, (2010)

By incorporating histone deacetylase (HDAC) inhibitory functionality into the pharmacophore of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitor...

CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.

Cancer Res. 70 , 3647-3656, (2010)

Receptor tyrosine kinase inhibitors have recently become important therapeutics for a variety of cancers. However, due to the heterogeneous and dynamic nature of tumors, the effectiveness of these age...